Drug intelligence / Profile preview

PA-001

Development stage: Phase 1
Lead developer: PeptiAID
Modality: Cyclic Peptides → Modified Peptides → Peptides
Administration: Intravenous

Overview

PA-001 is a novel macrocyclic peptide developed by PeptiDream Inc. It is being investigated as a potential treatment for COVID-19. Its mechanism of action involves targeting the highly conserved S2 subunit of the SARS-CoV-2 spike protein, which has shown in vivo efficacy in mouse models. Clinical studies in healthy subjects have demonstrated its safety and favorable pharmacokinetics.

Targets

S2 (SARS-CoV-2 spike S2 subunit)

Beyond the preview

Go deeper on PA-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PA-001.

Explore the full profile